ConductScience.org, home

Paper28964701

Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.

Bazinet M and 13 others. Lancet Gastroenterol Hepatol, 2017. Cited by 210 papers, by iCite.

Cite this record

ConductScience Library. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. Papers, record 28964701. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28964701

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
PubMed
Journal
Lancet Gastroenterol Hepatol
PubMed
Year
2017
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
210
iCite
Relative citation ratio, by iCite
7.85
iCite
Revised in PubMed
2018-12-02
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bazinet MMichel
2Pântea VVictor
3Cebotarescu VValentin
4Cojuhari LLilia
5Jimbei PPavlina
6Albrecht JJeffrey
7Schmid PPeter
8Le Gal FFrédéric
9Gordien EEmmanuel
10Krawczyk AAdalbert
11Mijočević HHrvoje
12Karimzadeh HHadi
13Roggendorf MMichael
14Vaillant AAndrew

Source PubMed

Download CSV of authors

Topics23

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antiviral AgentsMajor topic
Hepatitis BMajor topic
Hepatitis DMajor topic
Interferon-alphaMajor topic
Nucleic AcidsMajor topic
Polyethylene GlycolsMajor topic
PolymersMajor topic
Adolescent
Adult
Alanine Transaminase
Anemia
Aspartate Aminotransferases
Coinfection
Drug Therapy, Combination
Female
Humans
Liver
Male
Middle Aged
Neutropenia
Recombinant Proteins
Thrombocytopenia
Young Adult

Source PubMed

Download CSV of topics

Trials3

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT02233075REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infectionDerived from the trialYesClinicalTrials.gov
NCT02876419A Long Term Follow-up Study of Patients From the REP 301 ProtocolDerived from the trialYesClinicalTrials.gov
NCT05683548Replicor Compassionate Access ProgramBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Erratum in29254619Correction to Lancet Gastroenterol Hepatol 2017; 2: 877-89.https://conductscience.org/library/papers/29254619PubMed
Comment in28964702Nucleic acid polymers: much-needed hope for hepatitis D?https://conductscience.org/library/papers/28964702PubMed

Download CSV of comments and corrections

Cited by125

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 210 citations.

PMIDTitleJournalYearIn PapersSource
42866838Tobevibart plus elebsiran in hepatitis D: crossing a therapeutic threshold.Transl Gastroenterol Hepatol2026https://conductscience.org/library/papers/42866838PubMed
41684842Unveiling DNAJB12 and DNAJB14 as crucial chaperones in hepatitis B and D virus particle morphogenesis.iScience2026https://conductscience.org/library/papers/41684842PubMed
41642349Insight into the Biology of Hepatitis B Virus and Recent Therapeutic Approaches.Curr Microbiol2026https://conductscience.org/library/papers/41642349PubMed
41214393Beyond viral suppression: assessing the immunotherapeutic potential of bepirovirsen for chronic hepatitis B.Hepatol Int2026https://conductscience.org/library/papers/41214393PubMed
41179730Hepatitis B functional cure: Current and future perspective.World J Hepatol2025https://conductscience.org/library/papers/41179730PubMed
41149045Chronic Hepatitis B: Current Management and Future Directions.Diseases2025https://conductscience.org/library/papers/41149045PubMed
41023586Genomic medicine in hepatology: mechanisms and liver treatment strategies.Mol Med2025https://conductscience.org/library/papers/41023586PubMed
41011799Hepatitis Delta Virus Infection: An Overview.Pathogens2025https://conductscience.org/library/papers/41011799PubMed
40872814Updates on Recent Advancements in Hepatitis D Virus Treatment.Viruses2025https://conductscience.org/library/papers/40872814PubMed
40790753Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D.Virol J2025https://conductscience.org/library/papers/40790753PubMed
40677987The Management of Chronic Hepatitis B: 2025 Guidelines Update from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada.Can Liver J2025https://conductscience.org/library/papers/40677987PubMed
40624334Identification of low-molecular compounds that inhibit envelope formation of hepatitis B virus.Sci Rep2025https://conductscience.org/library/papers/40624334PubMed
40620504Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights.Liver Res2025https://conductscience.org/library/papers/40620504PubMed
40606936Hope on the horizon: Emerging therapies for hepatitis D.World J Hepatol2025https://conductscience.org/library/papers/40606936PubMed
40575639Advances in treatment of hepatitis delta virus infection: Update on novel investigational drugs.World J Virol2025https://conductscience.org/library/papers/40575639PubMed
40528594[Research progress on new drugs for the treatment of chronic hepatitis B virus infection].Zhonghua Gan Zang Bing Za Zhi2025https://conductscience.org/library/papers/40528594PubMed
40087915Frequency, Severity and Impact of Pegylated Interferon Alpha-Associated Flares in Hepatitis D Infection.J Viral Hepat2025https://conductscience.org/library/papers/40087915PubMed
40008233Current and future therapeutic options for chronic hepatitis D virus infection.Front Cell Infect Microbiol2024https://conductscience.org/library/papers/40008233PubMed
39958926B cell dysfunction in chronic hepatitis B virus infection.Liver Res2021https://conductscience.org/library/papers/39958926PubMed
39858515Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases.Biomolecules2025https://conductscience.org/library/papers/39858515PubMed

See all 125 cited byDownload CSV of cited by

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
INTERFERON ALFA-2ACHEMBL2108508Derived from the trial1https://conductscience.org/library/drugs/CHEMBL2108508

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28964701

GET https://conductscience.org/api/papers/v1/28964701/cited_by?page=2